Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $300
Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. CRL | 0.00 |
Morgan Stanley analyst Ricky Goldwasser maintains Charles River (NYSE:
CRL) with a Overweight and raises the price target from $260 to $300.
